With the continuous efforts in research and development, various companies are developing therapies, NeuroVax (Immune Response BioPharma), CNM-Au8 (Clene Nanomedicine), Tolebrutinib (SAR442168) (Sanofi), Evobrutinib/M2951 (Merck Healthcare KGaA), and many others are expected to enter the 7MM market by 2032.
DelveInsight’s “Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Multiple Sclerosis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Multiple Sclerosis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Multiple Sclerosis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Multiple Sclerosis: An Overview
Multiple Sclerosis (MS) is an unpredictable, autoimmune disease that affects the central nervous system. In MS, the body’s own immune system produces cells, and proteins (antibodies) to attack the fatty substance, myelin, which is responsible for protecting the nerve fibers. This is often characterized by relapsing episodes of neurologic impairment followed by remissions.
The damaged myelin forms scar tissue (sclerosis). Often the nerve fiber is also damaged. When any part of the myelin sheath or nerve fiber is damaged or destroyed, nerve impulses traveling to and from the brain and spinal cord are distorted or interrupted. People with Multiple Sclerosis generally develop symptoms in their late 20s, experiencing visual and sensory disturbances, limb weakness, gait problems, and bladder and bowel syndromes. Initially, they may have partial recovery, but over time they develop progressive disability.
Multiple Sclerosis-affected individuals may experience a variety of symptoms, physically, emotionally, mentally, and psychologically. The severity and types of symptoms differ among individuals; thus, symptoms differ among different people.
Multiple Sclerosis Market Key Facts
-
The market size of Multiple Sclerosis in the seven major markets was found to be USD 22,381 million in 2020.
-
The total 7MM prevalent cases of Multiple Sclerosis in 2022 were approximately 1,275,800 cases. The cases are expected to increase by 2032.
-
The prevalent cases of Multiple Sclerosis in the United States were found to be approximately 723,500 cases.
-
Among EU-5 countries, Germany had the highest number of prevalent cases of Multiple Sclerosis, which were approximately 211,601 cases in 2021. As per DelveInsight’s analysis, this will increase by 2032. On the other hand, the prevalent population of Multiple Sclerosis in Spain was found to be approximately 45,425 cases which as per DelveInsight’s analysis was the lowest in EU-5.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Multiple Sclerosis pipeline therapies. It also thoroughly assesses the Multiple Sclerosis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Multiple Sclerosis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Multiple Sclerosis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Multiple Sclerosis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Multiple Sclerosis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Multiple Sclerosis Epidemiology, Segmented as –
-
Total Prevalent Cases of Multiple Sclerosis in the 7MM [2019–2032]
-
Prevalence of Multiple Sclerosis Based on Age in the 7MM [2019–2032]
-
Prevalence of Multiple Sclerosis Based on Age in the 7MM [2019–2032]
-
Phenotype-specific prevalent cases of Multiple Sclerosis in the 7MM [2019–2032]
-
Extent of Disability (EDSS) in Multiple Sclerosis in the 7MM [2019–2032]
Multiple Sclerosis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Multiple Sclerosis market or expected to be launched during the study period. The analysis covers the Multiple Sclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares Multiple Sclerosis drugs based on their sale and market share.
The report also covers the Multiple Sclerosis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Multiple Sclerosis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Multiple Sclerosis Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/multiple-sclerosis-market
Multiple Sclerosis Therapeutics Analysis
The Multiple Sclerosis treatment market looks promising as the market is emerging with newer acute treatments that have been designated by the FDA to treat Multiple Sclerosis. Several major pharma and biotech companies are developing therapies for Multiple sclerosis. Currently, TG Therapeutics is leading the therapeutics market with its Multiple sclerosis drug candidates in the most advanced stage of clinical development.
Multiple Sclerosis Companies Actively Working in the Therapeutics Market Include
TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, GeNeuro SA, Sanofi, Bristol-Myers Squibb, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, Biogen, RemeGen Co., Ltd., Antisense Therapeutics, Immune Response BioPharma, Biocad, AB Science, Genentech, Novartis, Pipeline Therapeutics, ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, and many others.
Emerging and Marketed Multiple Sclerosis Therapies Covered in the Report Include:
-
Ublituximab: TG Therapeutics
-
IMU-838: Immunic
-
ATA188: Atara Biotherapeutics
-
ANK-700: ANOKION
-
NeuroVax: Immune Response BioPharma Inc.
-
CNM-Au8: Clene Nanomedicine
-
Tolebrutinib (SAR442168): Sanofi
-
Evobrutinib/M2951: Merck Healthcare KGaA
-
Ublituximab: TG Therapeutics, Inc.
-
ALKS 8700: Alkermes/Biogen
-
Arbaclofen (Arbaclofen ER): Osmotica Pharmaceutical
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/multiple-sclerosis-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Multiple Sclerosis Competitive Intelligence Analysis
4. Multiple Sclerosis Market Overview at a Glance
5. Multiple Sclerosis Disease Background and Overview
6. Multiple Sclerosis Patient Journey
7. Multiple Sclerosis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Multiple Sclerosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Multiple Sclerosis Unmet Needs
10. Key Endpoints of Multiple Sclerosis Treatment
11. Multiple Sclerosis Marketed Therapies
12. Multiple Sclerosis Emerging Drugs and Latest Therapeutic Advances
13. Multiple Sclerosis Seven Major Market Analysis
14. Attribute Analysis
15. Multiple Sclerosis Market Outlook (In US, EU5, and Japan)
16. Multiple Sclerosis Companies Active in the Market
17. Multiple Sclerosis Access and Reimbursement Overview
18. KOL Views on the Multiple Sclerosis Market
19. Multiple Sclerosis Market Drivers
20. Multiple Sclerosis Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/multiple-sclerosis-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Hemorrhoids Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Hemorrhoids market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Hemorrhoids market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/